P
PTC Therapeutics
A science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease
At a glance
- Founded
- 1998
- Headquarters
- South Plainfield, United States
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning PTC Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later21 investors entered at this stage
- HEHealthCap
- LFLongwood Fund
- HBHBM BioVentures
- JAJennison Associates
- HIHBM Healthcare Investments
- NHNovo Holdings
- CGCDIB Capital Group
- RURutgers university
- ACAdage Capital
- CBCredit Suisse First Boston
- DVDelphi Ventures
Cercano Management- MFManulife Financial
- BCBay City Capital
- CECelgene
- CSCredit Suisse
- NTNew Medical Technologies
- TGThe Column Group
- AVAmgen Ventures
- BCBrookside Capital
- CBCDI Bioscience
Source: Dealroom Talent Intelligence.
Alumni founders
Former PTC Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
KTKailera TherapeuticsEst. 2024
Ron RenaudUnited States
Stanisław PikulPolandGlobal footprint
team presence
across markets
Patents
118 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about PTC Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PTC Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.